Pulsed Field Ablation Versus Standard Ablation for Heart Rhythm Problems
Compares pulsed field ablation with standard ablation in adults with ventricular tachycardia.
Key facts
- Who runs it
- Pasquale Santangeli
- Where
- Cleveland, United StatesSee the site
- Trial code
- Registry title
- Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 16 Jun 2025
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- RFA Ablation
- PFA Ablation
- Record updated
- 3 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart disease after a heart attack who have repeated episodes of a dangerous fast heartbeat from the lower heart chambers (ventricular tachycardia). It compares two ways of treating the heart rhythm by catheter ablation.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Ischemic heart disease with a prior heart attack. Sustained monomorphic ventricular tachycardia: at least 2 documented episodes with an ICD, at least 1 without an ICD, or VT that keeps coming back despite heart rhythm medicines or ICD interventions. Left ventricular ejection fraction of 20% or more on an ultrasound of the heart within 90 days before enrollment.
- Earlier treatment
- People cannot have had a catheter or surgical ablation of VT within the past 2 months. Those who already have an ICD or take rhythm medicines may join as described above.
Main reasons for not taking part
- Idiopathic VT or a mobile blood clot in the left ventricle
- New York Heart Association class IV heart failure or cardiogenic shock (unless due to incessant VT)
- Acute coronary syndrome or heart surgery within the past 2 months
- Estimated glomerular filtration rate below 30 ml/min/1.73m2
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Age ≥18 years
- Ischemic heart disease with prior myocardial infarction
- Left ventricular ejection fraction ≥20% estimated by transthoracic echocardiography (TTE) within 90 days prior to enrollment
- Documented sustained monomorphic VT with any of the following characteristics:; ≥2documented episodes in patients with implantable cardioverter defibrillators (ICD); ≥1 documented episode(s) in patients without ICD; Recurrent VT despite antiarrhythmic medications (ineffective, contraindicated or not tolerated) or ICD interventions
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
Who cannot take part
- Acute coronary syndrome within the preceding 2 months (if incessant VT ≥1 month before enrollment)
- Any concomitant congenital heart disease
- Prior catheter or surgical ablation of VT within the past 2 months
- For individuals with no pre-existing ICD: Ineligibility for an ICD implant
- New York Heart Association class IV heart failure
- Cardiac surgery within the past 2 months
- Active infection
- Severe left heart valvular heart disease (aortic/mitral stenosis or regurgitation)
- Present mechanical heart valve
- Clinical, laboratory or imaging evidence of active ischemia
- Unable to provide informed consent
- Idiopathic VT
- Mobile LV thrombus
- Comorbidity likely to limit survival to <12 months
- Estimated glomerular filtration rate <30 ml/min/1.73m2
- Thrombocytopenia or coagulopathy
- Contraindication to heparin
- Pregnancy or lactation
- Anticipated need for epicardial mapping and ablation
- Pre-existing LVAD or other hemodynamic assist device
- cardiogenic shock unless it is due to incessant VT
Where in United States
- Cleveland ClinicCleveland, United StatesContact: Pasquale Santangeli, MD, PhDTaking people
About the trial
What the trial wants to find out
ASCEND is a randomized controlled open-label pilot study evaluating the safety and effectiveness of pulsed field ablation (PFA) with the novel FARAPOINT catheter compared to the standard radiofrequency (RFA) ablation with ThermoCool ST/FlexAbility SE/ThermoCool ST SF/TactiFlex SE of ventricular tachycardia (VT) in the patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator (ICD). The study hypothesis is that the PFA ablation is more efficient compared to the RFA technique but retains a comparable safety profile.
The 2 groups in the trial
- RFA AblationExisting treatment, for comparison
VT ablation with ThermoCool ST, FlexAbility SE, ThermoCool ST SF or TactiFlex SE catheters
- PFA AblationTreatment being tested
VT ablation with FARAPOINT catheter
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pulse Field Ablation for Post-Infarction Ventricular Tachycardia: the ASCEND Pilot Study
- Plain-language title
- Pulsed Field Ablation Versus Standard Ablation for Heart Rhythm ProblemsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 September 2026